CureToday: UC enrolling patients for glioblastoma trial
A new clinical trial at the University of Cincinnati is studying the effectiveness of a new two-pronged immunotherapy treatment procedure to treat the most aggressive and deadly type of brain tumors, called glioblastomas. Originating from healthy brain cells, glioblastomas can form in any area of the brain.
Soma Sengupta, MD, PhD, said the trial will administer two immunotherapy drugs in tandem with each other. She noted previous research has shown a single-arm immunotherapy treatment has not been effective, leading to the combination therapy being tested in the trial.
In collaboration with the Dana-Farber Cancer Insitute in Boston, a teaching affiliate of Harvard Medical School, researchers aim to enroll 24 patients in the Phase 1 study.
For more trial and enrollment information, contact Alex Love at lovea4@ucmail.uc.edu.
Featured photo at top of glioblastoma cells in culture courtesy of National Cancer Institute.
Related Stories
UC expert weighs in on current MASH treatment approaches
June 5, 2026
As MedCentral recently reported, pending broader pharmacologic approvals for metabolic dysfunction-associated steatohepatitis (MASH), lifestyle modifications remain the go-to intervention.
State continues support for the Ohio Cyber Range
June 5, 2026
The Ohio Cyber Range Institute at the University of Cincinnati recently received $227,000 from the Ohio Controlling Board., reported Local 12 News. The OCRI manages the Ohio Cyber Range on behalf of the state. It is a statewide, collaborative network that supports cybersecurity programs across Ohio.
UC alumni-led band The National named among greatest living American songwriters
June 4, 2026
UC-connected band The National, co-founded by DAAP alumni, has been named to The New York Times Magazine readers’ list of the 100 Greatest Living American Songwriters.